recently featured posts we've got 70502 articles so far

JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation

Nov20

Tokyo, Nov 20, 2014 – (ACN Newswire) – JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine (C.I.M.N), a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. The new formulation converts iodine[1] into […]

Intellipharmaceutics Announces Appointment of New Chief Financial Officer [Kuwait News Agency]

Nov20

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has appointed Domenic Della Penna as its new Chief Financial Officer (CFO) effective November 24, 2014.Mr. Della Penna brings considerable expertise and industry experience to the Company. […]

Dont let other formats steal market share

Nov19

While supermarkets have been a phenomenally successful format, accounting for a large proportion of the food retail market, their market share continues to be under pressure as new formats emerge and others raise their appeal.Combined, e-commerce, c-stores, drugstores and club all pose a significant threat as they seek to grab a greater share of consumers […]

Ranbaxy sues US drug regulator for revoking approvals [India Business] [Times of India]

Nov19

NEW DELHI: Drug maker Ranbaxy Laboratories, which is yet to resolve its long pending issues with the US drug regulator, has sued US Food and Drug Administration (US FDA) for revoking approvals granted to the firm for launching low-cost versions of two bestselling medicines Nexium and Valcyte used in treatment of heartburn and for infection […]

Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)]

Nov19

Mumbai: Ranbaxy Laboratories, the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca’s heartburn drug Nexium and Roche’s antiviral Valcyte in the US.According to analysts, Ranbaxy could have gained $250 million had […]

RANBAXY SUES USFDA FOR REVOKING DRUG APPROVALS

Nov19

Ranbaxy Laboratories Ltd has sued the US Food and Drug Administration (FDA) for revoking the tentative approvals of Nexium and Valcyte. The FDA has also withdrawn six-month market exclusivity of Valcyte. The USFDA had banned export of drugs manufactured at the plants of Ranbaxy in India to the US. Ranbaxy had paid fines of $500 […]

Federal Regulators Announce the Recall of Mayhem Dietary Supplements After Laboratory Testing Reveals Undeclared Drugs, Parker Waichman LLP Comments

Nov19

Port Washington, New York (PRWEB) November 19, 2014 Parker Waichman LLP, a national law firm representing patients injured by drugs and medical devices comments on a recall of Mayhem dietary supplements, produced by Chaotic Labz of Atkins, Arkansas. The recalled supplements were recalled after distribution nationwide to online stores and nutritional supplement sellers. The recall […]

Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference

Nov19

PHOENIX, AZ (Marketwired) 11/19/14 Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:Conference: Wednesday, […]

AUXILIUM PHARMACEUTICALS INC FILES (8-K) Disclosing Other Events

Nov19

Item 8.01 Other EventsLitigation UpdateAs previously disclosed, Auxilium Pharmaceuticals, Inc. ("Auxilium" or the"Company") and FCB I Holdings Inc. ("FCB") have been litigating various matterswith Upsher-Smith Laboratories, Inc. ("Upsher-Smith") related to Upsher-Smith’sfiling of Paragraph IV certifications in connection with a 505(b)(2) New DrugApplication (the "505(b)(2) NDA") and an Abbreviated New Drug Application, ineach case, using Testim […]

PURAMED BIOSCIENCE INC.

Nov19

The following discussion and analysis of the Company’s financial condition andplan of operations should be read and considered along with its condensedfinancial statements and related notes included in this Quarterly Report on Form10-Q. Various statements have been made in this Quarterly Report on Form 10-Qthat may constitute "forward-looking statements." Forward-looking statements mayalso be made in […]